Peptide News Digest

#Pharmaceutical-Tariffs

2 stories

Regulatory · View digest

Section 232 Pharmaceutical Tariff Structure Took Effect Friday July 31, 2026 for the 17 Companies Named in Annex III of the Trump Administration Executive Order With 100% Duties on Patented Drug and Active Pharmaceutical Ingredient (API) Imports Absent an Onshoring Agreement (Which Reduces the Tariff to 20%); Broader Pharmaceutical Industry Faces September 29, 2026 Deadline for Additional Tariff Applicability; Generic Pharmaceuticals, Biosimilars, and Their Ingredients Are Expressly Excluded; Industry Response Ahead of the Deadline Includes Over $500 Billion in Announced US Pharmaceutical Manufacturing Investment Commitments Per Trump Administration Reporting With Independent Analyst Tallies of $370-480 Billion for the 2025-2030 Period

The Section 232 pharmaceutical tariff structure took effect Friday July 31, 2026 for the 17 companies named in Annex III of the Trump administration Executive Order. Tariff structure: 100% duties on patented drug and active pharmaceutical ingredient (API) imports absent an onshoring agreement; companies that negotiated an onshoring agreement before the July 31 deadline receive a reduced 20% tariff. The broader pharmaceutical industry faces a September 29, 2026 deadline for additional tariff applicability at the higher rates. Generic pharmaceuticals, biosimilars, and their associated ingredients are expressly excluded from Section 232 at this time (President Trump separately announced Tuesday July 21 that imported generics would face zero tariffs for two years starting August 2028). Industry response ahead of the July 31 deadline: over $500 billion in announced US pharmaceutical manufacturing investment commitments per Trump administration reporting. Independent analyst tallies documented $370-480 billion in announced US pharma manufacturing investment for the 2025-2030 period. Companies affected include Novo Nordisk, Eli Lilly, Merck, AstraZeneca, Sanofi, AbbVie, Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen. Drawback relief provisions apply for API and finished-drug exports made from imported components. The tariff structure was formally imposed via the Executive Order 120 days before the July 31 effective date.

Regulatory · View digest

President Trump's Section 232 Pharmaceutical Tariffs Take Effect Friday July 31, 2026 for the 17 Companies Named in the Initial Tranche of the Section 232 National-Security Investigation Announced April 1, 2025 and Formally Initiated April 30, 2026; The Broader Pharmaceutical Industry Faces a September 29 Deadline for Additional Tariff Applicability, With the Peptide-and-Obesity Sponsors (Novo Nordisk, Eli Lilly, Merck, AstraZeneca, Sanofi, AbbVie, Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen) All Facing Potential 25% Import Duties Depending on Manufacturing-Location Documentation

President Trump's Section 232 pharmaceutical tariffs took effect Friday July 31, 2026 for the 17 companies named in the initial tranche of the Section 232 national-security investigation. The Section 232 pathway allows the President to impose tariffs on imports that threaten national security; the pharmaceutical investigation was announced April 1, 2025 by the Commerce Department under the Trump administration and formally initiated April 30, 2026. Companies in the initial tranche face tariffs on active pharmaceutical ingredient (API) and finished-drug imports depending on manufacturing-location documentation; the broader pharmaceutical industry faces a September 29 deadline for additional tariff applicability. Peptide-and-obesity-relevant sponsors including Novo Nordisk (Wegovy/Ozempic semaglutide, primarily manufactured in Denmark), Eli Lilly (Zepbound/Mounjaro tirzepatide and Foundayo orforglipron, primarily manufactured in Ireland and Indiana), Merck (LIPFENDRA/enlicitide macrocyclic peptide PCSK9, manufacturing across US and Ireland), AstraZeneca (elecoglipron and biologics portfolio), Sanofi (Dupixent dupilumab), AbbVie (Skyrizi and Rinvoq), Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen all face potential 25% import duties depending on manufacturing-location documentation. President Trump also announced Tuesday July 21 that imported generic drugs would face zero tariffs for two years starting August 2028, providing a two-year runway before generic tariffs begin.